Tom Fox on market expansion
From Tandem Diabetes executive chairman: Global uncertainity may cause investor hesitation · · CNBC Television
“About 30% of type 1 diabetics are using a pump, so we are going to expand that market where we actually are calling those daily injectors coming over to a pump. That was a big part of our growth.”
On , Tom Fox, Chief Human Resources Officer at TANDEM DIABETES CARE INC, spoke about market expansion during Tandem Diabetes executive chairman: Global uncertainity may cause investor hesitation on CNBC Television.
About Tom Fox
Tom Fox, Chief Human Resources Officer at Tandem Diabetes Care, has not been quoted in the provided material. The transcript and quotes feature Kim Blickenstaff, the company's executive chairman, discussing business performance and strategy in a September 2019 interview. Blickenstaff stated that the company's sales rates accelerated from Q1 to Q2 and that fundamentals remained intact. He attributed growth partly to converting daily insulin injectors to pump users, noting that about 30% of type 1 diabetics use a pump. Blickenstaff also addressed manufacturing decisions, saying the company keeps production in San Diego to maintain quality control and coordination with development engineers. He expressed a preference for manufacturing in America for this product. Regarding future products, he predicted FDA approval within the year and said a launch would be "almost instantaneous" due to the Tandem Device Updater, which enables software upgrades without hardware changes. He mentioned gaining traction in Europe and that clinical trial results presented at the American Diabetes Association had generated broad awareness in the medical community.